Success Metrics

Clinical Success Rate
86.0%

Based on 104 completed trials

Completion Rate
86%(104/121)
Active Trials
0(0%)
Results Posted
62%(64 trials)
Terminated
17(12%)

Phase Distribution

Ph phase_3
61
44%
Ph phase_4
44
32%
Ph not_applicable
11
8%
Ph phase_1
9
6%
Ph phase_2
11
8%

Phase Distribution

9

Early Stage

11

Mid Stage

105

Late Stage

Phase Distribution136 total trials
Phase 1Safety & dosage
9(6.6%)
Phase 2Efficacy & side effects
11(8.1%)
Phase 3Large-scale testing
61(44.9%)
Phase 4Post-market surveillance
44(32.4%)
N/ANon-phased studies
11(8.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.2%

104 of 125 finished

Non-Completion Rate

16.8%

21 ended early

Currently Active

0

trials recruiting

Total Trials

139

all time

Status Distribution
Completed(104)
Terminated(21)
Other(14)

Detailed Status

Completed104
Terminated17
unknown14
Withdrawn4

Development Timeline

Analytics

Development Status

Total Trials
139
Active
0
Success Rate
86.0%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (6.6%)
Phase 211 (8.1%)
Phase 361 (44.9%)
Phase 444 (32.4%)
N/A11 (8.1%)

Trials by Status

unknown1410%
withdrawn43%
completed10475%
terminated1712%

Recent Activity

Clinical Trials (139)

Showing 20 of 139 trialsScroll for more
NCT03118713Phase 4

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Terminated
NCT05975528Phase 4

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes

Unknown
NCT03917940Not Applicable

Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride

Completed
NCT05099198

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Completed
NCT05162183

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

Completed
NCT01951339Not Applicable

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Completed
NCT05663736Phase 4

Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes

Unknown
NCT05538819

The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure

Completed
NCT05468879Not Applicable

Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects

Completed
NCT00775684Not Applicable

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Completed
NCT05386186Phase 4

The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

Unknown
NCT02956044Phase 1

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Completed
NCT02649465Phase 4

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Completed
NCT02769481Phase 3

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed
NCT03332771Phase 3

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Completed
NCT00106340Phase 3

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Completed
NCT04470310Phase 4

Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination

Unknown
NCT02973477Phase 4

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Completed
NCT02964572Not Applicable

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Completed
NCT02419612Phase 3

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Completed

Drug Details

Intervention Type
DRUG
Total Trials
139